Manageability and Safety Assessment of Sepraspray in Abdominal Surgery.

N/ACompletedNCT00813397

Genzyme, a Sanofi Company210 enrolled

Overview

This study will examine the performance of SeprasSpray in patients undergoing abdominal surgery (laparoscopic).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

210

Conditions

Adhesion Prevention

Interventions

SeprasprayDEVICE

Max. 10g of Sepraspray

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients 18 years old and over that require laparoscopic abdominal surgery Exclusion Criteria: * Patients who are pregnant or have an ongoing infectious complications from a previous surgery

Locations (15)

CHU Amiens Nord

Amiens, France

Hopital Avicenne

Bobingy, France

Hopital Beaujon

Clichy, France

Outcomes

Primary Outcomes

Morbidity

Time frame: 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.